The government announced on Tuesday that booster doses will be offered to the most vulnerable people starting next week as part of a plan to “keep the lid” on infectious diseases during the winter.
For people in their 70s and older, care home residents and staff, front-line healthcare professionals, and clinically highly vulnerable adults, a third dose is prioritized in the UK and booster jabs will be 50 within the next few months. Deployed to most adults over the age of.
After more comprehensive data are available, a wider population of booster doses will be considered.
The Joint Committee on Vaccination and Immunization (JCVI) recommends a “mix and match” approach to booster rollouts, with both Pfizer and Moderna jabs as one other vaccine, including AstraZeneca jab. I gave it to all eligible people, whether they received it or not. Of their previous dose.
Professor Wei Shen Lim, chair of JCVI’s Covid-19 immunization, said the committee chose the Pfizer and Modana vaccines.
It is understood that there is more available scientific evidence for the long-term efficacy of mRNA jabs against other vaccines.
JCVI quoted data from the Cov-Boost trial released last week by the University of Southampton Hospital. This indicates that the Pfizer vaccine is well tolerated as a third dose in patients and results in a strong booster response.
After data from the Cov-Boost study suggested that a full dose of jab was not needed for comprehensive protection, he added that the Moderna vaccine should be offered as a half dose.
The government-funded Cov-Boost study also reviewed the safety and efficacy of vaccines produced by AstraZeneca, Novabax, Varneva, Janssen, and CureVac, but none of them are recommended by JCVI for the UK booster program. Hmm.
This means that AstraZeneca jabs are likely to be excluded from the initial stages of booster jab deployment if the Minister takes note of JCVI’s recommendations.
This decision could hurt a British-Swedish company that was once touted as the key to a break from the British pandemic.
AstraZeneca vaccines delivered using adenoviral vectors rather than mRNA technology have proven useful in previous UK vaccination campaigns.
Official estimates indicate that by September 1, approximately 48.9 million doses of AstraZeneca jab had been administered throughout the United Kingdom. That’s almost 53 percent of all jabs distributed in the UK.
This is one of the three Covid jabs currently being given in the UK on the first and second doses, along with the Pfizer and Moderna vaccines.
AstraZeneca’s jab is also one of two vaccines approved by UK drug regulators last week for a potential booster campaign in the UK.
The Medicines and Healthcare Products Regulatory Agency (MHRA) has recommended both AstraZeneca and Pfizer vaccines for the UK booster program, and June Raine has declared it “safe and effective” for the third dose. bottom.
But AstraZeneca’s boss warned last week that he was in a hurry to provide boosters to more people, robbing scientists of data on how well vaccines work if they move too fast. I added that it would be.
write in TelegraphCEO Pascal Soriot and Vice President Sir Mene Pangaros said the decision to give the most vulnerable booster jabs “wise” but “widely populated” a third jab He said it needs to be based on clinical data.
At a press conference on Tuesday, Professor Shen Lim refused to rule out the recommendation of the AstraZeneca vaccine in later expansion of the booster campaign, adding that the JCVI “keeps our options open.” rice field.
“I don’t think I can say much about future booster programs because I don’t know what will happen just because I don’t have the data,” he said. “I think you need to keep the options open. At this point, I don’t want to exclude them.”
Sources close to AstraZeneca said Me The company has completed data on the endurance of the defenses provided by the Covid vaccine.
They also added that AstraZeneca could shift its focus to global demand for Covidjab as domestic interest in AstraZeneca’s medicines is beginning to diminish.